<?xml version="1.0" encoding="UTF-8"?>
<p>Phytochemical compounds from Valerianaceae have great potential as drugs for neurodegenerative diseases (
 <xref ref-type="fig" rid="plants-10-00846-f001">Figure 1</xref>). The compounds (–)-(8R)-neonardochinone A, (+)-(8S) neonardochinone A, and nardochinins A–D isolated from 
 <italic>N. jatamansi</italic> exhibit anti-AD activity using the humanized 
 <italic>Caenorhabditis Elegans</italic> AD pathological model [
 <xref rid="B115-plants-10-00846" ref-type="bibr">115</xref>]. Lignans and iridoids isolated from 
 <italic>V. amurensis</italic> showed neuroprotective activity against Aβ-induced toxicity in PC12 cells [
 <xref rid="B35-plants-10-00846" ref-type="bibr">35</xref>,
 <xref rid="B99-plants-10-00846" ref-type="bibr">99</xref>,
 <xref rid="B119-plants-10-00846" ref-type="bibr">119</xref>]. AD is associated with the production and deposition of the β-amyloid peptide (Aβ) in the brain [
 <xref rid="B23-plants-10-00846" ref-type="bibr">23</xref>]. Several compounds isolated from 
 <italic>V. jatamansi</italic> such as jatadoids A and B, jatairidoids A and B, valeriandoids A–C, chlorovaltrate, valerilactones A and B, and bakkenolide-H have been studied to have neuroprotective properties in MPP+-induced Parkinson’s disease model in vitro [
 <xref rid="B43-plants-10-00846" ref-type="bibr">43</xref>,
 <xref rid="B44-plants-10-00846" ref-type="bibr">44</xref>,
 <xref rid="B105-plants-10-00846" ref-type="bibr">105</xref>,
 <xref rid="B127-plants-10-00846" ref-type="bibr">127</xref>]. Sesquiterpenoids from 
 <italic>V. officinalis</italic> showed AChE inhibitory activity in vitro [
 <xref rid="B53-plants-10-00846" ref-type="bibr">53</xref>,
 <xref rid="B131-plants-10-00846" ref-type="bibr">131</xref>]. AChE inhibitors are clinically used to treat neuropsychiatric symptoms of AD, PD, dementia, and schizophrenia. These compounds are promising lead compounds for discovering drugs for AD and PD.
</p>
